Pembrolizumab in Treating Patients With Malignant Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Reversing Therapy Resistance With Epigenetic-Immune Modification
- Status
- TERMINATED
- Phase
- PHASE2
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety Study of SEA-CD40 in Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE1
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
- Status
- COMPLETED
- Phase
- PHASE3
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
MK-3475 as Maintenance Therapy in Extensive Stage SCLC
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
- Status
- COMPLETED
- Phase
- PHASE3
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab +/- Bevacizumab for Recurrent GBM
- Status
- COMPLETED
- Phase
- PHASE2